Skip to main content
Premium Trial:

Request an Annual Quote

GeneMachines Licenses Microarray Printing Technology from Incyte

NEW YORK, July 23 – GeneMachines has licensed two patents covering microarray fabrication technology from Incyte Genomics, the company said Monday.

The license will allow GeneMachines, based in San Carlos, Calif., to sell its microarray printing machines, the OmniGrid and OmniGrid Accent, with label licenses for research use. In a statement, the company made no mention of any changes to their microarraying products, which have been available to customers for several years.

Financial details were not disclosed.

The patents cover basic contact microarray printing technology for arraying DNA microarrays on solid substrates, GeneMachines said.

“We are excited to have worldwide licensing rights to this enabling technology which has become invaluable to genomics research," Scott Hunicke-Smith, CEO of GeneMachines, said in a statement.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.